Overactive Bladder (OAB) Clinical Trial
Official title:
Treatment of Refractory Overactive Bladder (OAB) With OnabotulinumtoxinA vs. PTNS: TROOP Trial
This is a prospective cohort study of women with overactive bladder OAB (dry or wet) who have failed 2 prior treatments, including behavioral modification, pelvic floor physical therapy, and/or OAB medication (anticholinergics or mirabegron), and have chosen either OnabotulinumtoxinA (BTX) injection or percutaneous tibial nerve stimulation (PTNS) as their next treatment. OAB-dry refers to patients with OAB who do not have urge urinary incontinence; OAB-wet refers to patients with OAB and urge urinary incontinence. Eligible patients will be approached for study participation after they have decided to proceed with BTX or PTNS.
Prior to initiation of BTX or PTNS, patients will undergo a standardized evaluation including urodynamics study (UDS) if not previously done in the past year and pelvic organ prolapse quantification (POPq) exam if not previously done in past 6 months. Subjects will also complete quality of life questionnaires and 3-day voiding diary prior to initial treatment. Follow up questionnaires will be completed at 3 months either in office, if patient has a routine visit scheduled with provider and questionnaires can be completed at that visit or questionnaires will be mailed with return postage for participant to mail completed questionnaires back. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00507169 -
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
|
Phase 2 | |
| Completed |
NCT02216214 -
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
|
Phase 4 | |
| Completed |
NCT02294396 -
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
|
Phase 4 | |
| Completed |
NCT01936870 -
Drug Use Investigation for Toviaz
|
||
| Completed |
NCT03846895 -
Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)
|
N/A | |
| Completed |
NCT03903094 -
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
|
||
| Terminated |
NCT04641975 -
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
|
Phase 3 | |
| Completed |
NCT00366002 -
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
|
Phase 4 | |
| Completed |
NCT02138747 -
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
|
Phase 4 | |
| Completed |
NCT03602508 -
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
|
||
| Completed |
NCT03572231 -
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
|
||
| Completed |
NCT05211193 -
Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
|
||
| Completed |
NCT04562090 -
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
|
Phase 4 | |
| Completed |
NCT00282932 -
Detrol LA In Men With Overactive Bladder.
|
Phase 4 | |
| Completed |
NCT01639794 -
Vesitirim™ in Men Postmarketing Observational Study
|
N/A | |
| Withdrawn |
NCT01317810 -
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
|
N/A | |
| Completed |
NCT00742833 -
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
|
Phase 2 |